Takeda is a global biopharmaceutical company that develops and sells prescription medicines across six core areas: gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines. Takeda’s largest product is ENTYVIO, a biologic used to treat ulcerative colitis and Crohn’s disease. Takeda follows a branded pharmaceutical business model, investing in R&D to discover and commercialize novel drugs. Revenue is driven by prescription volume and pricing, which are protected by patents and regulatory exclusivity. A distinct part of the business involves plasma-derived therapies, requiring Takeda to operate a vertically integrated network of donation centers and manufacturing facilities to produce protein treatments. Takeda’s current strategy focuses on advancing a pipeline of potential blockbuster treatments for conditions like narcolepsy and psoriasis to offset revenue erosion from older products losing patent protection. To manage R&D risk and supplement internal discovery, Takeda frequently enters into licensing deals and external partnerships. The company aims to improve profitability by scaling new product launches while controlling administrative expenses.